About NGB Diagnostics
NGB Diagnostics is a company based in Delhi (India) by Rakesh Maurya. It operates as a B2B. NGB Diagnostics offers products and services including Whole Genome Sequencing, Whole Exome Sequencing, RNA Sequencing, Protein Identification, and iTRAQ Protein Quantification. NGB Diagnostics operates in a competitive market with competitors including Abcam, Arbor Biotechnologies, Singleron, Stem Cell Technologies and Octant, among others.
- Headquarter Delhi, India
- Founders Rakesh Maurya
- SectorsHealthcare
- Email••••••••
- Website ngbdx.com
- Social Facebook
- Legal Name Ngb Diagnostics Private Limited
- Date of Incorporation 05 Jun, 2012
- Jurisdiction New Delhi, Delhi, India
- Annual Revenue₹1.93 Cr
FY 2025 · -33% YoY
- Net Profit₹3.7 Lakh
FY 2025 · 2% margin
- EBITDA₹7.2 Lakh
FY 2025 · 4% margin
Associated legal entities of NGB Diagnostics
NGB Diagnostics operates through Ngb Diagnostics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Ngb Diagnostics Private Limited CIN U74999DL2012PTC236945 | Active | 05 Jun 2012 | New Delhi, Delhi | ₹1.9 Cr | – | 2 | View details |
Products & Services of NGB Diagnostics
NGB Diagnostics offers a comprehensive portfolio of products and services, including Whole Genome Sequencing, Whole Exome Sequencing, RNA Sequencing, Protein Identification, and iTRAQ Protein Quantification.
Service for sequencing entire genomes for research.
Sequencing of exomes for targeted genetic analysis.
Analysis of RNA transcripts for gene expression studies.
Identification of proteins using advanced techniques.
Quantification method for proteomic profiling.
Board of directors of Ngb Diagnostics Private Limited (NGB Diagnostics)
Ngb Diagnostics Private Limited is the primary company behind NGB Diagnostics. The board of Ngb Diagnostics Private Limited currently have 2 directors; the longest-serving is Rakesh Kumar Maurya, appointed in 2012. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rakesh Kumar Maurya DIN 05224587 | Director | 05 Jun 2012 | 14 yrs 4 mo | Ngb Diagnostics Private Limited |
| Amit Singh Rawat DIN 07592480 | Director | 18 Aug 2016 | 10 yrs 1 mo | Ngb Diagnostics Private Limited |
People of NGB Diagnostics
1 people are tracked at NGB Diagnostics (1 in leadership).
| Name | Role | Group |
|---|---|---|
| Founder, CEO | Leadership |
Complete people profiles for NGB Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of NGB Diagnostics
Figures of Ngb Diagnostics Private Limited, the primary company behind NGB Diagnostics, for FY 2025. Revenue was ₹1.93 Cr (-33% year on year). Net profit was ₹3.7 Lakh (2% margin). EBITDA was ₹7.2 Lakh (4% margin). Revenue has grown at a compounded annual rate of -27% over three years and +14% over five years.
- ₹1.93 CrRevenue · FY 2025 · -33% YoY
- ₹3.7 LakhNet profit · 2% margin
- ₹7.2 LakhEBITDA · 4% margin
- ₹1 LakhPaid-up capital
- -27%Revenue CAGR, 3 years
- +14%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Ngb Diagnostics Private Limited are on its company page.
Detailed financial statements for NGB Diagnostics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of NGB Diagnostics
NGB Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, Arbor Biotechnologies, Singleron, Stem Cell Technologies and Octant, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| abcam.com | 1998 | Cambridge, United Kingdom | $78.8M | 405 | Biological reagents and antibodies are developed for life science research. | |
| arbor.bio | 2016 | Cambridge, United States | $304.1M | 117 | Genomic technologies and drug discovery platforms are provided. | |
| singleron.bio | 2018 | Hagen, Germany | $84.48M | – | Developer of single-cell multi-omics platform for clinical research and molecular diagnosis | |
| stemcell.com | 1993 | Vancouver, Canada | $11.92M | 129 | Developer of cell culture media and ancillary reagents for life science research | |
| octant.bio | 2017 | Los Angeles, United States | $110M | 63 | Human cell interaction platform is provided for drug discovery. | |
| meridianbioscience.com | 1976 | Ohio, United States | – | – | Molecular diagnostic device and kits | |
| teknova.com | 1996 | Hollister, United States | – | 290 | Molecular biology reagents and kits are supplied for research applications. |
Detailed competitors of NGB Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NGB Diagnostics
The website of NGB Diagnostics (ngbdx.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▲ 89.1% vs previous month
Similar companies to NGB Diagnostics
10 companies that operate in the same segment as NGB Diagnostics (Clinical Genomics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Panomic profiling technologies are developed for cancer precision medicine. | 1996 | Irving, Texas, United States | USD 1.23 B | – | 1,339 | |
Genomics-based diagnostic tests for cancer are provided. | 2010 | Cambridge, Massachusetts, United States | USD 96.5 M | – | – | |
Digital molecular biology analytics are developed for disease management. | 2012 | Carlsbad, California, United States | USD 95.02 M | – | 46 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Genomic database for clinical research is provided. | 2015 | San Francisco, California, United States | USD 435 M | – | – | |
Genomic sequencing and diagnosis software is provided for healthcare. | 2011 | Menlo Park, California, United States | USD 87.3 M | USD 69.65 M | 229 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about NGB Diagnostics
NGB Diagnostics is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.
Rakesh Maurya is the current CEO of NGB Diagnostics. They have also founded this company.
The primary company behind NGB Diagnostics, Ngb Diagnostics Private Limited, reported revenue of ₹1.93 Cr for FY 2025, down 33% year on year.
NGB Diagnostics Private Limited, founded in 2012, delivers high-quality genomics and proteomics services using advanced bioinformatic pipelines. They specialize in whole genome sequencing, RNA sequencing, and protein analysis for clinical diagnostics, pharmaceutical, RD, and agro-food sectors. Based in India, they focus on affordable solutions with certified laboratories and cater to clients in healthcare and biotechnology industries.
NGB Diagnostics's top competitors include Abcam, Arbor Biotechnologies and Meridian Bioscience.
NGB Diagnostics offers Whole Genome Sequencing, Whole Exome Sequencing, RNA Sequencing, Protein Identification, and iTRAQ Protein Quantification.
NGB Diagnostics operates through Ngb Diagnostics Private Limited.
The legal entities of NGB Diagnostics currently have 2 directors, including Rakesh Kumar Maurya, Amit Singh Rawat.